ERBB2 and colorectal carcinoma: Beyond highly seductive but quite rare targets, such as HER2 amplification and NTRK fusions, the most striking revolution for targeted therapies in CRC patients comes from ICIs that were a breakthrough for patients with MSI/dMMR tumors.